Thanks to Banca Monte dei Paschi di Siena for hosting the international NIBIT Meeting in its historical headquarter.
Cancer Bio-Immunotherapy XII

NIBIT

Banca Monte dei Paschi di Siena
Piazza Salimbeni, Siena
Rocca Salimbeni di Siena
Banca Monte dei Paschi di Siena

Programe
Scientific

October 8-10 2015

Siena
Arrival/Registration/Light Lunch

12:00

Arrival/Registration/Light Lunch

14:00

Welcome addresses

SESSION 1. Regulatory mechanisms of anti-tumor immune responses

Chairs: Matteo Bellone (Milan, Italy); Vincenzo Russo (Milan, Italy)

14:15

Vincenzo Bronte (Verona, Italy): Macrophages and myeloid-derived suppressor cells as modulators of anti-tumor immune responses.

14:40

Barbara Seliger (Halle, Germany): Immunomodulatory microRNAs as a novel mechanism to revert immune escape of tumors.

15:05

Licia Rivoltini (Milan, Italy): pH-regulators in tumor immunity.

15:30

Antonio Sica (Rozzano, Italy): Targeting myeloid cell differentiation and function in cancer.

Coffee break

SESSION 2. Mutational profile of tumors and the identification of neo-antigens

Chairs: Alberto Amadori (Padua, Italy); Giorgio Parmiani (Siena, Italy)

16:30


16:55

Ugur Sahin (Mainz, Germany): Individualized RNA vaccines targeting the mutanome.

17:20

Zlatko Trajanoski (Vienna, Austria): Immune phenotypes and antigens of solid cancers.

15:05

Invited Abstract:

Mario Leonardo Squadrito (Lausanne, Switzerland): Dicer control of macrophage polarization and tumor response to immunotherapy.

15:55

Beatrice Schuler-Thurner (Erlangen, Germany): Randomized, open-label Phase III study to evaluate the adjuvant vaccination with tumor RNA-loaded autologous dendritic cells versus observation of patients with resected monosomy 3 uveal melanoma.

16:10

Coffee break

18:00

General Assembly of the NIBIT

20:00

Dinner

Thursday October 8
SESSION 3. Tumor microenvironment
Chairs: Enrico Proietti (Rome, Italy); Paola Zanovello (Padua, Italy)

08:55 Franco M. Marincola (Doha, Qatar): Determinant of immune responsiveness among different cancers.
09:20 Matteo Bellone (Milan, Italy): The relationship between TH17 and microbiota in multiple myeloma.
09:45 Andrea Anichini (Milan, Italy): A subset of CD8+ early effector T cells at tumor site in NSCLC.

Invited Abstract:
10:10 Samuel Huber (Hamburg, Germany): Differentiation and inflammation: Role of TH17 cells.

10:25 Chiara Pozzi (Milan, Italy): The anti-EGFR monoclonal antibody cetuximab combined with chemotherapy triggers immunogenic cell death.

10:40 Gianfranca Correa (Milan, Italy): HIF-1α induces 24-Hydroxycholesterol-dependent pancreatic neuroendocrine tumor angiogenesis.

10:55 Coffee break

SESSION 4. The evolving role of immunotherapy of cancer
Chairs: Christoph Huber (Mainz, Germany); Umberto Tirelli (Aviano, Italy)

11:15 Pierre Coulie (Brussels, Belgium): Tumor antigens and immunostimulatory antibodies.
11:40 Soldano Ferrone (Boston, USA): Intracellular tumor antigens as a source of targets for antibody-based immunotherapy of solid tumors.
12:05 Luana Calabrò (Siena, Italy): Immunotherapy of thoracic malignancies.

12:30 Christoph Huber (Mainz, Germany): An Introduction to the European Alliance for Immuno-Oncology (EAIO).

12:45 Mariangela Figni (Milan, Italy): Hooking TRAIL-R2 to ‘educate’ immune system to recognize cancer cell.

13:00 Carla Bucchi (Rome, Italy): Combining Type 1 IFN and 5-Aza-2’-Deoxyxycytidine to improve anti-tumor response against melanoma.


13:30 Lunch
SESSION 5. News from Companies
Chairs: Michael Giordano (New York, USA)
Roberto Camerini (Rome, Italy)

14:15 Michael Giordano (BMS, New York, USA): ImmunOncology at BMS.

14:40 Ramy Ibrahim (Astra Zeneca, Gaithersburg, MD, USA): ImmunOncology at Astra Zeneca

15:05 Elliot Chartash (MSD, New York, USA): ImmunOncology at MSD


15:55 Jean-Marie Cuillerot (EMD-Serono, Boston, MA, USA): ImmunOncology at EMD-Serono.

16:20 Coffee breack.

SESSION 6. New aspects of immune responses for immunotherapy. Joint session NIBIT-SIICA
Chairs: Michele Maio (Siena, Italy)
Angelo Vacca (Bari, Italy)

16:40 Mario Paolo Colombo (Milan, Italy): Myeloid cells in tumorigenesis and immunoregulation

17:05 Ennio Carbone (Catanzaro, Italy): New opportunity in melanoma: NK cells.

17:30 Anna Maria Di Giacomo (Siena, Italy): The NIBIT clinical studies.

17:55 Cecilia Garlanda (Milan, Italy): The humoral pattern recognition molecule PTX3 acts as an extrinsic oncosuppressor by regulating Complement-dependent tumor-promoting inflammation.

Selected Abstracts

18:20 Pier Francesco Ferrucci (Milan, Italy): Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: upfront markers for ipilimumab treatment in metastatic melanoma.

18:35 Paola Nisticò (Rome, Italy): Anti-tumor polyfunctional CD8 T cells elicited by dacarbazine treatment before peptide vaccination depends on AKT activation sustained by ICOS.

19:00 Guest Lecture
Daniela Minerva (Rome, Italy): Perché l’immunoncologia piace tanto ai media e chi sono i suoi nemici? Introduces Michele Maio (Siena, Italy).

20:30 Social dinner
SESSION 7. Adoptive Cell Therapy
Chairs: Lorenzo Moretta (Rome, Italy)
Pier Francesco Ferrucci (Milan, Italy)

08:30 Per Thor Straten (Copenhagen, Denmark):
ACT in melanoma.

08:55 Giacomo Oliveira (Milan, Italy):
Editing and tracking T cells for cancer immunotherapy.

09:20 Lorenzo Moretta (Rome, Italy):
NK cells in the therapy of high risk leukemias.

09:45 Gaia Zuccolotto (Padua, Italy):
Cave CAR: A high affinity scFv in conjunction with a highly efficient CD28-CD137 signalling domain can be detrimental for T cells.

10:00 Dario Sangiolo (Turin, Italy):
Targeting soft tissue sarcomas by cytokine-induced killer (CIK) cells redirected with anti-CD44v6 chimeric antigen receptor.

10:15 Coffee break

SESSION 8. Ongoing and prospective NIBIT activities and collaborations
Chairs: Massimo Di Nicola (Milan, Italy)
Ruggero Ridolfi (Meldola, Italy)

10:35 Cristina Maccalli (Siena, Italy):
The NIBIT translational studies.

11:00 Paola Queirolo (Genoa, Italy):
IMI activities.

11:25 Michele Maio (Siena, Italy):
ImmunOncology web-site.

11:40 Gianluca Giacobini (Siena, Italy):
BRAF inhibitors can either inhibit or potentiate anti-tumor T cell responses in melanoma patients depending on the origins of T lymphocytes.

11:55 Silvio Monfardini (Milan, Italy):
An introduction to cancer in the elderly before embarking upon immunotherapy trials. Introduces Giorgio Parmiani (Siena, Italy).

12:30 NIBIT AWARDS NOMINATIONS

12:45 NIBIT Elections - Results

13:15 Lunch

14:00 Adjourn